Durata Therapeutics to Present at the 2013 Wedbush Securities Life Sciences Management Access Conference

Durata Therapeutics to Present at the 2013 Wedbush Securities Life Sciences
Management Access Conference

CHICAGO, Aug. 6, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX)
announced today that Paul R. Edick, CEO, will present an overview of the
Company at the Wedbush Securities Life Sciences Management Access Conference
on Tuesday, August 13, 2013 at 3:05 PM ET at the Le Parker Meridien in New
York City.

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and
commercialization of novel therapeutics for patients with infectious diseases
and acute illnesses. Durata has completed two global Phase 3 clinical trials
with its lead product candidate, dalbavancin, under investigation for the
treatment of patients with acute bacterial skin and skin structure infections
caused by susceptible gram-positive bacteria.

Forward-looking statements

Any statements in this press release about Durata's future expectations, plans
and prospects constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995, as amended. Actual results
may differ materially from those indicated by such forward-looking statements.
Durata anticipates that subsequent events and developments will cause its
views to change. However, while Durata may elect to update these
forward-looking statements at some point in the future, Durata specifically
disclaims any obligation to do so.

CONTACT: Allison Wey
         Durata Therapeutics, Inc.
         Vice President, Investor Relations and Public Affairs
         (312) 219-7017
         awey@duratatherapeutics.com

Durata Therapeutics, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.